Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers

Pharmacological Research

Volumn 59, Issue 6, 2009, Pages 393-398

  Borobia, Alberto M ^a   Novalbos, Jesús ^b   Guerra López, Pedro ^a   López Rodríguez, Rosario ^b   Tabares, Beatriz ^a   Rodríguez, Vanesa ^b   Abad Santos, Francisco ^a   Carcas, Antonio J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

CYP2D6; Mirtazapine; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; MIRTAZAPINE; REXER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD CHEMISTRY; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; ELECTROCARDIOGRAPHY; EVALUATION; FEMALE; GENOTYPE; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SPAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VALIDATION STUDY;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MASS SPECTROMETRY; MIANSERIN; SEX FACTORS; SPAIN; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 67349129782     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.02.006     Document Type: Article

References (21)

1. Remeron package insert (Organon-US), Rev 4/96, Rec 9/96. Available in: http://www.drugs.com/MMX/Mirtazapine.html.
2. Timmer C.J., Sitsen J.M., and Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38 6 (2000) 461-474
3. Dodd S., Boulton D.W., Burrows G.D., De Vane C.L., and Norman T.R. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol 16 7 (2001) 541-544
4. Brockmöller J., Meineke I., and Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 81 May (5) (2007) 699-707
5. Menoyo A., del Rio E., and Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 24 Sep-Oct (5) (2006) 381-385
6. Grasmader K., Verwohlt P.L., Dragicevic A., Von Widdern O., Zobel A., Hiemke C., et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 60 7 (2004) 473-480
7. Kirchheiner J., Henckel H.B., Meineke I., Roots I., and Brockmöller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 24 6 (2004) 647-652
8. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. London; 26 July 2001.
9. Chen M.L., Lee S.C., Jee M.J., Schuirmann D.J., Lesko L.J., and Williams R.L. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68 (2000) 510-521
10. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., and Leeder J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83 Feb (2) (2008) 234-242
11. Abad-Santos F., Carcas A.J., Guerra P., Govantes C., Montuenga C., Gomez E., et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol 36 8 (1996) 748-751
12. Carcas A.J., Guerra P., Frías J., Soto A., Fernandez-Aijón A., Montuenga C., et al. Gender differences in the disposition of metronidazol. Int J Clin Pharmacol Ther 39 5 (2001) 213-218
13. Murphy Jr. G.M., Kremer C., Rodrigues H.E., and Schatzberg A.F. Pharmacogenetics of antidepressant medication intolerante. Am J Psychiatry 160 (2003) 1830-1835
14. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50 2 (1995) 222-239
15. Schwartz J.B. The influence of sex on pharmacokinetics. Clin Pharmacokinet 42 2 (2003) 107-121
16. Walle T., Walle K., Cowart T.D., and Conradi E.C. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46 3 (1989) 257-263
17. Kashuba A.D., Nafziger A.N., Kearns G.L., Leeder J.S., Shirey C.S., Gotschall R., et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8 Oct (5) (1998) 403-410
18. Labbe L., Sirois C., Pilote S., Arseneault M., Robitaille N.M., Turgeon J., et al. Effect of gender, sex hormones, time variables, and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 1085 (2000) 425-438
19. Hamelin B.A., Desgagnés V., Rail J., Bogaty P., Morin J., and Turgeon J. CYP2D6 ultrarapid metabolism and response to metoprolol. Pharmacotherapy 17 (1997) 1081
20. Hagg S., Spigset O., and Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51 2 (2001) 169-173
21. Tamminga W.J., Wemer J., Oosterhuis B., et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55 3 (1999) 177-184